IASO104 for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma (NCT07185490) | Clinical Trial Compass
Not Yet RecruitingEarly Phase 1
IASO104 for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
40 participantsStarted 2026-02-15
Plain-language summary
This study is a single-center, open-label, dose-exploration trial designed to evaluate the tolerability and safety of different doses of IASO104 in patients with relapsed/refractory plasma cell neoplasms, determine the recommended dose of IASO104, and assess its pharmacokinetic and pharmacodynamic characteristics. Additionally, the study will preliminarily observe the efficacy of the investigational drug in a small sample of subjects with relapsed/refractory multiple myeloma.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age 18-75 years, any gender.
✓. Diagnosis of multiple myeloma (MM) per International Myeloma Working Group (IMWG) diagnostic criteria.
✓. Prior therapy requirements:
✓. Documented disease progression during/within 12 months after last anti-myeloma therapy (exemption: No 12-month requirement if last line was CAR-T).
✓. Measurable disease at screening (≥1 of the following):
✓. ECOG performance status 0-1.
✓. Life expectancy ≥12 weeks.
✓. Adequate organ function (all lab values within 7 days prior to enrollment):
Exclusion criteria
✕. Active graft-versus-host disease (GVHD) or requiring long-term immunosuppressive therapy.